{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:59:11Z","timestamp":1778950751227,"version":"3.51.4"},"reference-count":74,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The hepatitis C virus (HCV) is a common cause of chronic liver disease and liver cancer worldwide. Despite advances in curative therapies for HCV, the incidence of new infections is not decreasing at the expected rate to hit the World Health Organization (WHO) target for the elimination of HCV by 2030. In fact, there are still more new cases of infection in the United States and worldwide than are being cured. The reasons for the rise in new cases include poor access to care and the opioid epidemic. The clinical burden of HCV requires a multimodal approach to eradicating the infection. Vaccination would be an excellent tool to prevent incidence of new infections; however, the genetic diversity of HCV and its ability to generate quasispecies within an infected host make creating a broadly reactive vaccine difficult. Multiple vaccine candidates have been identified, but to date, there has not been a target that has led to a broadly reactive vaccine, though several of the candidates are promising. Additionally, the virus is very difficult to culture and testing candidates in humans or chimpanzees is ethically challenging. Despite the multiple barriers to creating a vaccine, vaccination still represents an important tool in the fight against HCV.<\/jats:p>","DOI":"10.3390\/pathogens10121619","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T22:06:10Z","timestamp":1639519570000},"page":"1619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hepatitis C Vaccination: Where We Are and Where We Need to Be"],"prefix":"10.3390","volume":"10","author":[{"given":"Vignan","family":"Manne","sequence":"first","affiliation":[{"name":"HCA Healthcare Graduate Medical Education, Las Vegas, NV 89148, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ryan","sequence":"additional","affiliation":[{"name":"Comprehensive Digestive Institute of Nevada, Las Vegas, NV 89148, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Wong","sequence":"additional","affiliation":[{"name":"HCA Healthcare Graduate Medical Education, Las Vegas, NV 89148, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Vengayil","sequence":"additional","affiliation":[{"name":"HCA Healthcare Graduate Medical Education, Las Vegas, NV 89148, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Abdul","family":"Basit","sequence":"additional","affiliation":[{"name":"Comprehensive Digestive Institute of Nevada, Las Vegas, NV 89148, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3189","authenticated-orcid":false,"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[{"name":"Liver Transplant Clinic, Loma Linda University, Loma Linda, CA 92350, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, October 19). Global Hepatitis Report. Available online: http:\/\/apps.who.int\/iris\/bitstream\/10665\/204370\/1\/WHO_HIS_SDS_2015.23_eng.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, progress, and challenges to hepatitis C vaccine development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_7","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (2021, July 02). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available online: https:\/\/www.hcvguidelines.org\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/j.gastro.2014.05.010","article-title":"Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus\u2013infected homosexual man","volume":"147","author":"Franco","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"Maylin","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C\u2013associated liver cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response","volume":"64","author":"Midgard","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_15","first-page":"110","article-title":"Barriers to treatment access for chronic hepatitis C virus infection: A case series","volume":"25","author":"Millman","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ofy076","DOI":"10.1093\/ofid\/ofy076","article-title":"Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: A national specialty pharmacy cohort study","volume":"5","author":"Gowda","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.epidem.2008.10.002","article-title":"Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users","volume":"1","author":"Hahn","year":"2009","journal-title":"Epidemics"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Scott, N., McBryde, E., Vickerman, P., Martin, N.K., Stone, J., Drummer, H., and Hellard, M. (2015). The role of a hepatitis C virus vaccine: Modelling the benefits alongside direct-acting antiviral treatments. BMC Med., 13.","DOI":"10.1186\/s12916-015-0440-2"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stone, J., Martin, N.K., Hickman, M., Hellard, M., Scott, N., McBryde, E., Drummer, H., and Vickerman, P. (2016). The potential impact of a hepatitis C vaccine for people who inject drugs: Is a vaccine needed in the age of direct-acting antivirals?. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156213"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Scott, N., Wilson, D.P., Thompson, A.J., Barnes, E., El-Sayed, M., Benzaken, A.S., Drummer, H.E., and Hellard, M.E. (2019). The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Med., 17.","DOI":"10.1186\/s12916-019-1411-9"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/hep.510250637","article-title":"The molecular virology of hepatitis C","volume":"25","author":"Major","year":"1997","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1099\/jgv.0.000672","article-title":"ICTV virus taxonomy profile: Flaviviridae","volume":"98","author":"Simmonds","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11984","DOI":"10.3748\/wjg.v21.i42.11984","article-title":"Progress in the development of vaccines for hepatitis C virus infection","volume":"21","author":"Ghasemi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yong, M.K.S., Her, Z., and Chen, Q. (2019). Humanized mouse models for the study of hepatitis C and host interactions. Cells, 8.","DOI":"10.3390\/cells8060604"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2893.2000.00201.x","article-title":"Properties of the hepatitis C virus core protein: A structural protein that modulates cellular processes","volume":"7","author":"Mclauchlan","year":"2000","journal-title":"J. Viral Hepat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.24523","article-title":"Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes","volume":"54","author":"Mazumdar","year":"2011","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0966-842X(99)01590-5","article-title":"Quasispecies in viral persistence and pathogenesis of hepatitis C virus","volume":"7","author":"Forns","year":"1999","journal-title":"Trends Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/JVI.02265-09","article-title":"Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection","volume":"84","author":"Liu","year":"2010","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1084\/jem.20041006","article-title":"CD8 epitope escape and reversion in acute HCV infection","volume":"200","author":"Timm","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI78794","article-title":"Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance","volume":"125","author":"Bailey","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.91.16.7792","article-title":"Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization","volume":"91","author":"Farci","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.510250530","article-title":"Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus","volume":"25","author":"Zibert","year":"1997","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection","volume":"197","author":"Shoukry","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1084\/jem.191.9.1499","article-title":"Analysis of successful immune responses in persons infected with hepatitis C virus","volume":"191","author":"Lechner","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Duncan, J.D., Urbanowicz, R.A., Tarr, A.W., and Ball, J.K. (2020). Hepatitis C virus vaccine: Challenges and prospects. Vaccines, 8.","DOI":"10.3390\/vaccines8010090"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1053\/j.gastro.2012.06.005","article-title":"Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus","volume":"143","author":"Park","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","unstructured":"Coates, S.K.G., Crawford, K., Dong, C., Wininger, M., and Houghton, M. (2003, January 6\u20138). Protection of chimpanzees against heterologous 1a viral challenge using a gpE1\/gpE2 heterodimer vaccine. Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/infdis\/jir423","article-title":"Clearance of genotype 1b hepatitis C virus in Chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies","volume":"204","author":"Verstrepen","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2003.09.010","article-title":"Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection","volume":"22","author":"Puig","year":"2004","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s007050050559","article-title":"Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees","volume":"144","author":"Esumi","year":"1999","journal-title":"Arch. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/jhep.2000.9877","article-title":"Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus(HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV","volume":"32","author":"Forns","year":"2000","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10896","DOI":"10.1128\/JVI.01179-08","article-title":"Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus","volume":"82","author":"Youn","year":"2008","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hep.21573","article-title":"Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity","volume":"45","author":"Rollier","year":"2007","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.21319","article-title":"CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus","volume":"44","author":"Puig","year":"2006","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.20934","article-title":"Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee","volume":"42","author":"Youn","year":"2005","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.vaccine.2009.02.045","article-title":"T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation","volume":"27","author":"Zubkova","year":"2009","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JVI.78.1.187-196.2004","article-title":"Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response","volume":"78","author":"Rollier","year":"2004","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","article-title":"Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees","volume":"104","author":"Elmowalid","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fimmu.2019.01145","article-title":"A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice","volume":"10","author":"Masavuli","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mar\u00edn, M.Q., P\u00e9rez, P., Ljungberg, K., Sorzano, C., \u00d3scar, S., Gomez, C.E., Liljestr\u00f6m, P., Esteban, M., and Garc\u00eda-Arriaza, J. (2019). Potent anti-hepatitis C virus (HCV) T cell immune responses induced in mice vaccinated with DNA-launched RNA replicons and modified vaccinia virus ankara-HCV. J. Virol., 93.","DOI":"10.1128\/JVI.00055-19"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14085","DOI":"10.1038\/s41598-019-50365-z","article-title":"HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen","volume":"9","author":"Filskov","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dawood, R.M., Moustafa, R.I., Abdelhafez, T.H., El-Shenawy, R., El-Abd, Y., El Din, N.G.B., Dubuisson, J., and El Awady, M.K. (2019). A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4571-5"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1038\/s41598-018-24762-9","article-title":"Immunological responses following administration of a genotype 1a\/1b\/2\/3a quadrivalent HCV VLP vaccine","volume":"8","author":"Christiansen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2018.03.036","article-title":"Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes","volume":"36","author":"Wei","year":"2018","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41467-019-09105-0","article-title":"Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection","volume":"10","author":"Hartlage","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/hep.30894","article-title":"Use of an outbred rat hepacivirus challenge model for design and evaluation of efficacy of different immunization strategies for hepatitis C virus","volume":"71","author":"Atcheson","year":"2020","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenecity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Law, J., Chen, C., Wong, J., Hockman, D., Santer, D.M., Frey, S.E., Houghton, M.A., Belshe, R.B., Bukh, J., and Jones, C.T. (2013). Hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059776"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2004.02.002","article-title":"A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers","volume":"22","author":"Depla","year":"2004","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4161\/hv.5.3.6614","article-title":"Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX\u2122 vaccine: A phase I study in healthy volunteers","volume":"5","author":"Drane","year":"2009","journal-title":"Hum. Vaccines"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_69","first-page":"115ra1","article-title":"Novel adenovirus-based vaccine induced broad and sustained T cell responses to HVC in Man","volume":"115","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection","volume":"9","author":"Hartnell","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"eaaz7715","DOI":"10.1126\/scitranslmed.aaz7715","article-title":"MHC class II invariant chain\u2013adjuvanted viral vectored vaccines enhances T cell responses in humans","volume":"12","author":"Esposito","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.4049\/jimmunol.1103008","article-title":"Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection","volume":"188","author":"Burke","year":"2012","journal-title":"J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hartlage, A., and Kapoor, A. (2021). Hepatitis C virus vaccine research: Time to put up or shutup. Viruses, 13.","DOI":"10.3390\/v13081596"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2468-1253(21)00073-X","article-title":"The hunt for a vaccine for hepatitis C virus continues","volume":"6","author":"Hepatology","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/12\/1619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:47:11Z","timestamp":1760168831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/12\/1619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":74,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pathogens10121619"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10121619","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]}}}